Cleared Traditional

VISION SGOT (AST) (K854982) - FDA 510(k) Clearance

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K854982 · Abbott Laboratories · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1986
Decision
33d
Days
Class 2
Risk

K854982 is an FDA 510(k) clearance for the VISION SGOT (AST). Classified as Nadh Oxidation/nad Reduction, Ast/sgot (product code CIT), Class II - Special Controls.

Submitted by Abbott Laboratories (Abbott Park, US). The FDA issued a Cleared decision on January 14, 1986 after a review of 33 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1100 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Abbott Laboratories devices

Submission Details

510(k) Number K854982 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 12, 1985
Decision Date January 14, 1986
Days to Decision 33 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
55d faster than avg
Panel avg: 88d · This submission: 33d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CIT Nadh Oxidation/nad Reduction, Ast/sgot
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CIT Nadh Oxidation/nad Reduction, Ast/sgot

All 51
Devices cleared under the same product code (CIT) and FDA review panel - the closest regulatory comparables to K854982.
EMDS(TM) ASPARTATE AMINOTRANSFERASE (AST) 67657/95
K863963 · Em Diagnostic Systems, Inc. · Nov 1986
SYSTEMATE (TM) ALANINE TRANSFERASE (ALT)
K863094 · Em Diagnostic Systems, Inc. · Aug 1986
VISION SGOT (AST) - ADDIT. OF WHOLE BLOOD CLAIM
K860465 · Abbott Laboratories · May 1986
AST(OPTIMIZED) REAGENT
K854503 · Sigma Diagnostics, Inc. · Nov 1985
ROCHE REAGENT FOR AST
K843109 · Roche Diagnostic Systems, Inc. · Nov 1984
SYSTEMATE GOT 67208
K843333 · Em Diagnostic Systems, Inc. · Sep 1984